pharma news today obesity drugs glp-1 How Supply and Demand for Weight Loss is Playing Out in 2026 New GLP-1 Pill Foundayo (Orforglipron)

CVS Restores Coverage of Lillys Zepbound, Adds Oral Obesity Drug Foundayo Nicholas Jacobus Key Takeaways Zepbounds return as a preferred option reverses a prior formulary exclusion that maintained Wegovy coverage, underscoring how net pricing and rebate contracting drive PBM obesity access decisions

Individuals with higher incomes and under age 55 were less likely to stop the medications, and those with obesity were more likely

Synthesis, optimization, and biological evaluation of corrinated conjugates of the glp-1r agonist exendin-4

Either a GP or clinician can advise on the best course of action

For dosing guidance after purchase, our semaglutide dosage chart in units and optimal timing guide cover everything you need for proper administration